Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
公司代碼EOLS
公司名稱Evolus Inc
上市日期Feb 08, 2018
CEOMoatazedi (David)
員工數量332
證券類型Ordinary Share
年結日Feb 08
公司地址520 Newport Center Dr Ste 1200
城市NEWPORT BEACH
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編92660-7022
電話19492844555
網址https://www.evolus.com/
公司代碼EOLS
上市日期Feb 08, 2018
CEOMoatazedi (David)